Skip to content
Loop Biz – Lifestyle
Author:
Moderna, Inc.
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
September 21, 2026
Moderna to Present at Upcoming Conferences in September 2026
September 1, 2026
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
August 28, 2026
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
August 27, 2026
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
August 27, 2026
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
August 5, 2026
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna’s Investigational Vaccine Against Bundibugyo Ebolavirus
August 4, 2026
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
July 31, 2026
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
July 16, 2026
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
July 9, 2026
1
2
3
Next Page
→